Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations Etoricoxib Tablets 120 mg (Pharmtechnology LLC, Republic of Belarus) and Arcoxia® Tablets 120 mg (Merck Sharp & Dohme B.V., Netherlands) in Healthy Volunteers Under Fasting Conditions

NCT04830579 is registered in ClinicalTrials.gov with Pharmtechnology LLC as lead sponsor.

NCT NCT04830579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04830579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Crossover Two Period Single Dose Bioequivalence Study of Two Formulations Etoricoxib Tablets 120 mg (Pharmtechnology LLC, Republic of Belarus) and Arcoxia® Tablets 120 mg (Merck Sharp & Dohme B.V., Netherlands) in Healthy Volunteers Under Fasting Conditions
Lead sponsor
Pharmtechnology LLC
Phase
Phase 1
Overall status
Unknown status
Start date
April 10, 2021
Completion date
April 28, 2021
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence